Wegovy

obesity overweight weight loss weigh
Biotech

Novo pushes ahead with amylin after seeing ph. 3 tolerability

The injectable amylin drug appears to have slightly lower efficacy but a more tolerable profile than Novo's approved obesity blockbuster Wegovy.
James Waldron Sep 16, 2025 8:12am
Doustdar
Favicon Fierce Pharma

Novo charts major restructuring, layoffs under new CEO

Sep 10, 2025 8:41am
Doustdar
Favicon Fierce Pharma

Novo Nordisk names new CEO as it cuts sales, profit outlook

Jul 29, 2025 10:10am
Ozempic syringe pen and measuring tape on blue background

Novo plots ph. 3 trials for next-gen obesity asset amycretin

Jun 13, 2025 10:35am
Novo Nordisk CEO
Favicon Fierce Pharma

Novo's longtime CEO Lars Fruergaard Jørgensen to step down

May 16, 2025 9:41am
base camp tent mountain summit

'All hands on deck' at Lilly as peers target obesity market

Aug 8, 2024 1:40pm